Research article · 6 Oct 2017
EditorialPublished 2012
Cancer Metastases and Clinical Therapies
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
More than 90% cancer deaths are caused by cancer metastasis. As cancer metastasis is the main cause of human deaths, we shall pay more attentions on it. Currently, treatment and chemotherapy are focused on primary tumors rather than metastatic processes. Antimetastatic drugs are often used as assistant therapy. So cancer patients’ survivals have been improved very little. To change this mindset, we highlight this problem by giving new perspectives and try to improve the outcome of chemotherapy of cancer patients from different possible ways. Human cancer metastasis is a long-evolving, multi-steps process that can only be treated or controlled by drugs or immuno-modulators by now. Human neoplasm metastasis, at least a month-long course, encompasses several different substages and affects or being affected by numerous genes and molecules. We have found that each drug or immuno-modulator might act differently within the various stages of a metastatic course. We, therefore, suggest that future antimetastatic therapy should be strategically optimized according to characteristics of metastatic processes in order to reach maximum therapeutic benefits. In this view, we propose, address and support this issue by using past literature evidence, our experimentations and existing biological, anatomical and pathologic characteristics.
Subjects
BiologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Review article · Oct 2021
Cancer stem cell biomarkers: critical roles, challenges, clinical applications and perspectives in cancer therapy
Opinion · 8 Nov 2017
Clinical Cancer Therapy, Personalized Chemotherapies
Conference abstract · 20 Nov 2013
Identification and characterization of annexin A1 as a clinically useful biomarker of responsiveness to PPARG ligand therapy in triple negative breast cancer
Conference abstract · 26 Nov 2018
Survivin and livin expression as prognostic markers in the primary breast cancer and their lymph node metastases
More from this journal
The newest in Cell & Developmental Biology.
Short communication · 1 Jul 2026
Progressive Emergence of Functional Layering Through Integrated Regulatory Synchronization in Multidomain Biological Systems
Opinion · 1 Jul 2026
Spatial Heterogeneity and Progressive Specialization in Multilayer Developmental Information Landscapes
Opinion · 1 Jul 2026
Developmental Trajectories Shaped by Interconnected Mechanical–Chemical Feedback Systems in Expanding Biological Architectures
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalCell & Developmental Biology
- SubjectBiology
- BylineArticles whose byline prints “Da-Yong Lu”
- BylineArticles whose byline prints “Ting-Ren Lu”
- BylineArticles whose byline prints “Shan Cao”

